Further Pharmaceutical Co. Ltd. (www.further-pharm.com) is an innovation-driven and service-oriented biopharmaceutical hi-tech company with global operations that develops and manufactures specialty and generic drugs, pharmaceutical intermediates and APIs. Subsidiary companies include Jiangsu Further Pharmaceutical Co. Ltd., Wuxi Further Pharmaceutical Co. Ltd. and Canada Further Pharma Inc.

Jiangsu Further Pharmaceutical Co. Ltd. was established in January 2012 at the exclusive medical-centric national level high-tech industrial park-Taizhou Medical City High-Tech Industrial Park. Main business of Jiangsu Further is the clinical research for drug development, including Phase I-IV trials, clinical pharmacokinetics (PK), bioequivalence (BE) studies. We have highly educated professional team of clinicians, clinical research associates, and medical monitors as well as reliable quality management and control system to ensure the compliance to ICH-GCP and Chinese GCP requirements and the acquisition of high quality clinical research data.

Wuxi Further Pharmaceutical Co., Ltd. is located at Wuxi City, China by the beautiful Tai Lake Shore and registered in prestigious Wuxi (Huishan) Life Science & Technology Industrial Park. We were founded with mission to create highest quality of global Research & Development, manufacturing and marketing chain for small molecule and biologies innovative and generic drugs as well as pharmaceutical intermediates, APIs, and macromolecule polymers/biomaterials with our own IP and innovative drug delivery/formulation technologies. Our R&D Center at Wuxi has Generic Drugs Bioequivalence Evaluation Platform, Medicinal Chemistry Platform, Impurities Directional Preparation Technology Platform, Innovative Formulation Platform, Analytical Technology Platform, as well as Clinical Research Platform.

Canada Further Pharma Inc. is located in Toronto, Canada with main focus of medical/pharmaceutical information and regulatory consulting, API DMF application, Drug products clinical development and IND/NDA submission, Reference listed drug procurement, medical raw material API and intermediates export/import. Our experienced North America team of scientists offer one-stop efficient service with opportunities for pharmaceutical companies from China and other regions to register their products with FDA, Health Canada or EMA in shortened time and lowered costs. Further Pharmaceutical Service includes regulatory consulting, CTA, IND or NDA/ANDA submission, and clinical development programs.